CN113651803B - 用于制备二苯基甲烷衍生物的方法 - Google Patents

用于制备二苯基甲烷衍生物的方法 Download PDF

Info

Publication number
CN113651803B
CN113651803B CN202110860586.9A CN202110860586A CN113651803B CN 113651803 B CN113651803 B CN 113651803B CN 202110860586 A CN202110860586 A CN 202110860586A CN 113651803 B CN113651803 B CN 113651803B
Authority
CN
China
Prior art keywords
compound
formula
reaction
mixture
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110860586.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113651803A (zh
Inventor
尹羲均
朴世换
尹址诚
崔珣奎
徐希静
朴恩婷
孔渶圭
宋光燮
金旼姝
朴劭屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Daewoong Pharmaceutical Co Ltd
Original Assignee
Green Cross Corp Japan
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113651803(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp Japan, Daewoong Pharmaceutical Co Ltd filed Critical Green Cross Corp Japan
Publication of CN113651803A publication Critical patent/CN113651803A/zh
Application granted granted Critical
Publication of CN113651803B publication Critical patent/CN113651803B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/005Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202110860586.9A 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法 Active CN113651803B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17
KR10-2016-0075910 2016-06-17
PCT/KR2017/006271 WO2017217792A1 (ko) 2016-06-17 2017-06-15 다이페닐메탄 유도체의 제조방법
CN201780036968.1A CN109311861B (zh) 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780036968.1A Division CN109311861B (zh) 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法

Publications (2)

Publication Number Publication Date
CN113651803A CN113651803A (zh) 2021-11-16
CN113651803B true CN113651803B (zh) 2022-10-28

Family

ID=60664449

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780036968.1A Active CN109311861B (zh) 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法
CN202110860586.9A Active CN113651803B (zh) 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780036968.1A Active CN109311861B (zh) 2016-06-17 2017-06-15 用于制备二苯基甲烷衍生物的方法

Country Status (29)

Country Link
US (2) US10640496B2 (enExample)
EP (2) EP3473621B1 (enExample)
JP (4) JP6763978B2 (enExample)
KR (2) KR102233229B1 (enExample)
CN (2) CN109311861B (enExample)
AU (1) AU2017285813B2 (enExample)
CA (2) CA3026756C (enExample)
CL (1) CL2018003645A1 (enExample)
CO (1) CO2018014018A2 (enExample)
DK (2) DK3473621T3 (enExample)
DO (1) DOP2018000287A (enExample)
EC (1) ECSP19000185A (enExample)
ES (2) ES2898336T3 (enExample)
HR (1) HRP20211670T8 (enExample)
HU (1) HUE056428T2 (enExample)
MA (2) MA50774B1 (enExample)
MX (2) MX392177B (enExample)
MY (1) MY203941A (enExample)
NZ (1) NZ749398A (enExample)
PE (2) PE20190467A1 (enExample)
PH (1) PH12018550206A1 (enExample)
PL (2) PL3473621T3 (enExample)
PT (2) PT3663292T (enExample)
RS (1) RS62550B1 (enExample)
SA (2) SA518400666B1 (enExample)
SG (2) SG11201811154QA (enExample)
SI (1) SI3663292T1 (enExample)
TN (1) TN2018000437A1 (enExample)
WO (1) WO2017217792A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
MX2021001732A (es) * 2018-08-13 2021-06-23 Daewoong Pharmaceutical Co Ltd Preparacion de intermedio util para la sintesis de inhibidor de sglt.
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
MX2022010220A (es) * 2020-02-27 2022-10-10 Daewoong Pharmaceutical Co Ltd Intermedio util para la sintesis de un inhibidor de sglt y metodo para preparar un inhibidor de sglt utilizando el mismo.
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
PE20231373A1 (es) * 2020-09-10 2023-09-07 Daewoong Pharmaceutical Co Ltd Metodo de sintesis para la preparacion de un intermedio de inhibidores de sglt
CN113200860B (zh) * 2021-04-29 2024-07-30 爱斯特(成都)生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
KR20230046784A (ko) * 2021-09-30 2023-04-06 주식회사 대웅제약 이나보글리플로진을 포함하는 약학 조성물
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR20230110001A (ko) * 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044194A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
KR20240044190A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
KR20240045138A (ko) 2022-09-29 2024-04-05 주식회사 대웅제약 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물
JP2025533903A (ja) 2022-10-05 2025-10-09 デーウン ファーマシューティカル カンパニー リミテッド エナボグリフロジンを含む腎障害及び/又は糖尿病の予防又は治療用薬学組成物{pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin}
JP2025541565A (ja) 2022-12-21 2025-12-19 デウン セラピューティックス インコーポレイテッド エナボグリフロジンを含む点眼剤の形態の医薬組成物
KR20240107660A (ko) 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물
KR102853437B1 (ko) * 2024-11-13 2025-09-04 대웅바이오(주) 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837941B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837948B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596564A (zh) * 2011-06-01 2014-02-19 株式会社绿十字 作为sglt2抑制剂的新的二苯基甲烷衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
KR100942622B1 (ko) * 2003-08-01 2010-02-17 미쓰비시 타나베 파마 코퍼레이션 나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물
PT2183263E (pt) 2007-07-26 2012-01-11 Lexicon Pharmaceuticals Inc Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio
AU2009275918A1 (en) * 2008-07-30 2010-02-04 Ferrer Internacional S. A. 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (en) * 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596564A (zh) * 2011-06-01 2014-02-19 株式会社绿十字 作为sglt2抑制剂的新的二苯基甲烷衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C-Aryl glucosides substituted at the 4"-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes;Baihua Xu et al.;《Bioorganic & Medicinal Chemistry Letters》;20110616;第21卷;4465-4470 *

Also Published As

Publication number Publication date
PT3663292T (pt) 2021-11-08
JP6763978B2 (ja) 2020-09-30
US20190382390A1 (en) 2019-12-19
SG10201911782RA (en) 2020-02-27
RS62550B1 (sr) 2021-12-31
SG11201811154QA (en) 2019-01-30
MA44545B1 (fr) 2020-05-29
KR102379584B1 (ko) 2022-03-29
CA3081033C (en) 2022-04-12
CN113651803A (zh) 2021-11-16
KR20170142904A (ko) 2017-12-28
RU2019101056A (ru) 2020-07-17
TN2018000437A1 (en) 2020-06-15
MA50774A1 (fr) 2021-03-31
US10640496B2 (en) 2020-05-05
MX385640B (es) 2025-03-18
JP7773506B2 (ja) 2025-11-19
RU2021129636A (ru) 2021-11-22
BR112018076243A2 (pt) 2019-03-26
CN109311861B (zh) 2021-08-24
SI3663292T1 (sl) 2022-01-31
US10889574B2 (en) 2021-01-12
ES2898336T3 (es) 2022-03-07
EP3473621B1 (en) 2021-08-04
WO2017217792A1 (ko) 2017-12-21
EP3473621A1 (en) 2019-04-24
EP3663292B1 (en) 2021-09-01
JP2021152054A (ja) 2021-09-30
MY203941A (en) 2024-07-25
DK3663292T3 (da) 2021-10-25
CO2018014018A2 (es) 2019-03-08
DK3473621T3 (da) 2021-09-06
DOP2018000287A (es) 2019-03-31
US20190169174A1 (en) 2019-06-06
MX2018015647A (es) 2019-04-11
ECSP19000185A (es) 2019-01-31
MA50774B1 (fr) 2022-02-28
PT3473621T (pt) 2021-10-04
EP3663292A1 (en) 2020-06-10
JP2019521985A (ja) 2019-08-08
HRP20211670T1 (hr) 2022-02-18
CA3026756A1 (en) 2017-12-21
NZ749398A (en) 2020-01-31
RU2019101056A3 (enExample) 2020-07-17
CA3026756C (en) 2021-03-02
MX2021008988A (es) 2022-05-05
AU2017285813A1 (en) 2019-01-17
HUE056428T2 (hu) 2022-02-28
MA44545A1 (fr) 2019-10-31
SA521422474B1 (ar) 2023-11-02
JP2023145481A (ja) 2023-10-11
PE20190467A1 (es) 2019-04-04
MX392177B (es) 2025-03-19
CN109311861A (zh) 2019-02-05
PH12018550206A1 (en) 2019-09-30
PE20240590A1 (es) 2024-03-21
JP7669206B2 (ja) 2025-04-28
AU2017285813B2 (en) 2020-02-06
PL3473621T3 (pl) 2022-01-10
PL3663292T3 (pl) 2022-01-17
SA518400666B1 (ar) 2021-11-30
HRP20211670T8 (hr) 2022-03-18
CA3081033A1 (en) 2017-12-21
JP7352509B2 (ja) 2023-09-28
ES2891825T3 (es) 2022-01-31
KR20210036892A (ko) 2021-04-05
MA44545B2 (fr) 2020-11-30
CL2018003645A1 (es) 2019-03-22
JP2020117528A (ja) 2020-08-06
KR102233229B1 (ko) 2021-03-29
EP3473621A4 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
CN113651803B (zh) 用于制备二苯基甲烷衍生物的方法
CN105001213B (zh) C-芳基糖苷衍生物、其药物组合物、制备方法及应用
JP7146067B2 (ja) Sglt阻害剤の合成に有用な中間体の製造
KR101770302B1 (ko) 다이페닐메탄 유도체의 제조방법
RU2814846C1 (ru) Способ получения производного дифенилметана
HK40002293B (zh) 用於制备二苯基甲烷衍生物的方法
HK40057423A (en) Method for producing diphenylmethane derivative
HK40057423B (en) Method for producing diphenylmethane derivative
HK40002293A (en) Method for producing diphenylmethane derivative
RU2797392C2 (ru) Способ получения производного дифенилметана
RU2774998C2 (ru) Способ получения производного дифенилметана
BR112018076243B1 (pt) Método para produzir um composto derivado de difenil metano e forma cristalina do composto produzido pelo dito método

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40057423

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20211116

Assignee: DAEWOONG PHARMACEUTICAL Co.,Ltd.

Assignor: GREEN CROSS Corp.

Contract record no.: X2023990000259

Denomination of invention: Method for preparing diphenylmethane derivatives

Granted publication date: 20221028

License type: Exclusive License

Record date: 20230217